translocations or amplifications on top of the genomic alterations previously existing in the original CLL, but lack the popular mutations noticed in Key DLBCL indicating they could correspond to a distinct biological category.Unfit patients also have the choice of venetoclax in addition obinutuzumab (VO) as frontline therapy. This relies on a sect